Combination Therapy for Cancer
AssigneeArk Therapeutics, Ltd.
InventorsHaritha SAMARANAYAKE, Jere PIKKARAINEN, Ann-Marie MAATTA, Seppo YLA-HERTTUALA
Life of this patent
Estimating the term…
Abstract
An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
Claims42
A method of treating glioblastoma multiforme, said method comprising the steps of:
- a. Diagnosing in a human patient glioblastoma multiforme;
- b. Identifying in said patient at least one glioblastoma multiforme tumor;
- c. Resectioning said glioblastoma multiforme tumor to remove at least part of said glioblastoma multiforme tumor and expose tumor bed tissue;
- d. Administering to said tumor bed tissue an AdHSV-tk adenoviral vector having a gene coding for thymidine kinase, whereby said AdHSV-tk adenoviral vector transfects said tumor bed tissue and said tumor bed tissue expresses said gene coding for thymidine kinase;
- e. Within about 5 to about 19 days after administering said adenoviral vector to said human patient, further administering to said human patient ganciclovir;
- f. Administering to said human patient temozolomide per os or by intravenous infusion.
An agent comprising a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning the another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
An agent comprising a vector having a functional gene, and a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, as a combined preparation for simultaneous, sequential or separate use in the therapy of a disease characterised by an impaired mismatch repair (MMR) pathway.
In a method of treating brain cancer in an immunocompetent human patient by administering temozolomide to said immunocompetent human patient, the improvement comprising:
- administering to said immunocompetent human patient a viral vector.
A kit comprising a viral vector and temozolomide, said viral vector and said temozolomide present in an amount effective to treat brain cancer in a human patient.
Dependencies are inferred from the claim text.